Abstract
Background
Visceral adiposity index (VAI) and lipid accumulation product (LAP) are comprehensive indicators to evaluate visceral fat and determine the metabolic health of individuals. Carotenoids are a group of naturally occurring antioxidants associated with several diseases. The purpose of this investigation was to explore the association between serum carotenoid concentration and VAI or LAP.
Methods
The data were obtained from the National Health and Nutrition Examination Survey between 2001 and 2006. The levels of serum carotenoids were evaluated using high-performance liquid chromatography. Multivariate linear regression models were employed to investigate the relationship between levels of serum carotenoids and VAI or LAP. The potential non-linear relationship was determined using threshold effect analysis and fitted smoothing curves. Stratification analysis was performed to investigate the potential modifying factors.
Results
In total, 5,084 participants were included in this population-based investigation. In the multivariate linear regressions, compared to the lowest quartiles of serum carotenoids, the highest quartiles were significantly associated with VAI, and the effect size (β) and 95% CI was − 0.98 (− 1.34, − 0.62) for α-carotene, − 1.39 (− 1.77, − 1.00) for β-carotene, − 0.79 (− 1.18, − 0.41) for β-cryptoxanthin, − 0.68 (− 0.96, − 0.39) for lutein/zeaxanthin, and − 0.88 (− 1.50, − 0.27) for trans-lycopene. Using piece-wise linear regression models, non-linear relationships were found between βcarotene and trans-lycopene and VAI with an inflection point of 2.44 (log2-transformed, ug/dL) and 3.80 (log2-transformed, ug/dL), respectively. The results indicated that α-carotene, β-cryptoxanthin, and lutein/zeaxanthin were linearly associated with VAI. An inverse association was also found between serum carotenoids and LAP after complete adjustments.
Conclusion
This study revealed that several serum carotenoids were associated with VAI or LAP among the general American population. Further large prospective investigations are warranted to support this finding.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12944-023-01945-6.
Keywords: Visceral fat, Serum carotenoids, Visceral adiposity index, Lipid accumulation product, NAHNES
Introduction
Over past decades, there has been a notable increase in the worldwide prevalence of obesity, driven by alterations in dietary habits and daily lifestyles [1]. Individuals who are obese, particularly those with an excessive buildup of visceral adipose tissue, have an increased prevalence of developing hypertension, diabetes, cardiovascular diseases (CVD), and cancer [2]. The visceral adiposity index (VAI) is a valid indicator assessing the distribution and dysfunction of visceral fat in adults [3]. Unlike traditional indexes, such as waist circumference (WC) and body mass index (BMI), which primarily focus on overall weight or abdominal circumference, the VAI considers multiple factors, such as anthropometric and metabolic parameters, allowing a comprehensive evaluation of visceral fat distribution. Therefore, VAI exhibits greater sensitivity in identifying unhealthy metabolic phenotypes associated with visceral adiposity, including conditions such as insulin resistance, dyslipidemia, and cardiovascular risk factors [4–7]. The lipid accumulation product (LAP) index has garnered attention in the field of metabolic research and is used to assess and indicate the status of abdominal lipid accumulation [8]. LAP has considerable predictive capabilities compared with traditional lipid profiles for CVD, chronic kidney disease, diabetes, and other related conditions [9–11]. Studies suggest that dietary factors have a remarkable effect on obesity and lipid metabolism [12, 13].
Carotenoids are a class of lipid-soluble pigments that exhibit orange, yellow, or red colors and function as antioxidants in the human body [14]. Over 95% of the carotenoids circulating in the bloodstream comprise β-carotene, α-carotene, β-cryptoxanthin, lutein/zeaxanthin, and lycopene [15]. Several carotenoids exert a range of bioactive effects due to the antioxidant and anti-inflammatory properties [16]. Carotenoids can decrease reactive oxygen species-induced damages, prevent lipid peroxidation, and participate in cellular signaling pathways regulating apoptosis [17, 18].
Previous studies have reported inconsistent findings with respect to the effects of carotenoids on obesity and related indices. Some studies showed an inverse relationship between carotenoids and weight, adipose tissue, and anthropometric measures in obese individuals [19, 20], whereas other studies have reported no effect [21, 22]. Furthermore, limited information is available about the correlation between serum carotenoids and VAI or serum carotenoids and LAP. Elucidating the relationship between serum carotenoids and VAI or LAP could offer several novel insights into carotenoids and lipid metabolism. This study explored the correlation between levels of serum carotenoids and VAI or LAP in general United States (U.S.) adults using data from National Health and Nutrition Examination Survey (NHANES).
Materials and methods
Study population
NHANES is a program carried out by the National Center for Health Statistics (NCHS) aimed at gathering data on nutritional and medical conditions using a representative sample of American population. Their sampling methods use a complex and multi-stage probability approach. This study involved 15,431 individuals (age ≥ 20 years) from NHANES between 2001 and 2006. After excluding people without complete data on the five primary serum carotenoids, individuals without a reliably measured VAI or LAP were further excluded. Individuals with missing data on covariates, such as age, sex, race, alcohol intake, and smoking status, were also excluded. Lastly, this study included 5,084 participants (Fig. 1). The protocol was authorized by the NCHS Ethics Review Board and each participant gave written informed consents.
Fig. 1.
Flowchart of participant selection
Exposure variable and outcomes
The measurement of five serum carotenoids was performed using high-performance liquid chromatography (HPLC) [23]. Information regarding participants was available on trans-βcarotene, cis-βcarotene, α-carotene, β-cryptoxanthin, lutein/zeaxanthin, and trans-lycopene. NHANES 2001–2002 did not provide information on total lycopene. The total βcarotene level was calculated by aggregating the cis-βcarotene and trans-βcarotene concentrations. Laboratory tests were performed to calculate measurements of triglycerides (TG), high-density lipoprotein (HDL), and total cholesterol (TC) in blood samples. The VAI score was calculated using both anthropometric and biochemical data using previously established equations as reported by Amato et al [3]. LAP score was calculated using WC and TG [24].
 |
 |
 |
 |
In the equations, WC and BMI are represented in cm and kg/m2, respectively. The units of TG and HDL are in mmol/L.
Covariates
Demographic data were collected via questionnaire interviews, which included age, sex, marital status, race, engagement in leisure-time physical activities, education level, and the family of poverty ratio. Weight divided by height squared was used to determine BMI. Alcohol consumption included never (< 12 drinks in lifetime), current (≥ 12 drinks and currently drinking) and former (no drink last year but ≥ 12 drinks in lifetime). Smoking status included former (≥ 100 cigarettes but not currently smoking), current (≥ 100 cigarettes and currently smoking) and never (< 100 cigarettes in lifetime). Hypertension was diagnosed according to systolic blood pressure ≥ 140 mmHg or diastolic ≥ 90 mmHg, a prior diagnosis, or a history of antihypertensive medications. Diabetes was diagnosed according to fasting glucose level (mmol/L) ≥ 7.0, glycohemoglobin (%) ≥ 6.5, the use of antidiabetic medications or insulin, or a prior diagnosis of diabetes mellitus by a physician. CVD was defined as having stroke, congestive heart failure, heart attack, angina, or coronary artery disease. All data are publicly available at www.cdc.gov/nchs/nhanes/.
Statistical analysis
All statistical analyses followed the NHANES analytic and reporting guidelines, which involved complex survey design factors [25]. The weighted analyses were conducted with the R package “survey.” Through dividing the 2-year weights by three, new 6-year weights were obtained. Individuals were classified into four quartiles according to serum β-carotene levels, based on the abundance and high antioxidant properties of β-carotene [26, 27]. Characteristics were represented as mean ± standard error (SE) for continuous variables, and proportions were applied to describe categorical parameters. The weighted chi-square analysis and the weighted one-way analysis were performed to detect any disparities in the descriptive analyses. Multivariate linear regression models were employed to calculate size effect (β) values and 95% confidence intervals (CIs) for the association between serum carotenoid levels and VAI or LAP. No covariate was adjusted in Model (1) Age and sex were modified in Model (2) Model 3 further included race, smoking status, alcohol intake, marital status, engagement in leisure-time physical activity, BMI, the family of poverty ratio, education level, TC, hypertension, diabetes, and CVD. The smoothed curve fits were constructed to evaluate the potential non-linear relationship. We employed a threshold effect analysis model to investigate the inflection point between log2-transformed serum carotenoids and VAI or LAP. Stratification analysis was conducted to explore the potential modifying factors. The analysis was considered statistically significant if the two-sided P-values ≤ 0.05. We conducted statistical analyses using R Studio (Version 4.2.2) and EmpowerStats (version 4 0.1).
Results
Characteristics of the study population
Table 1 provides weighted baseline characteristics of participants stratified by the β-carotene quartiles. Among the 5,084 participants, the average age was 46.29 ± 0.47 years, and 2,430 (49.74%) participants were female. The average serum concentration was 4.24 ± 0.18 ug/dL for α-carotene, 8.93 ± 0.18 ug/dL for β-cryptoxanthin, 23.05 ± 0.26 ug/dL for trans-lycopene, and 15.58 ± 0.22 ug/dL for lutein/zeaxanthin.
Table 1.
Baseline characteristics of study participants stratified by serum β-carotene quartiles
| variable | Serum β-carotene (ug/dl) | P value | ||||
|---|---|---|---|---|---|---|
| total | Q1 | Q2 | Q3 | Q4 | ||
| Age (year) | 46.29 ± 0.47 | 41.82 ± 0.54 | 44.11 ± 0.57 | 47.68 ± 0.74 | 52.49 ± 0.69 | < 0.001 |
| Sex, n (%) | < 0.001 | |||||
| Female | 2430 (49.74) | 476 (37.74) | 570 (48.47) | 635 (52.42) | 749 (62.38) | |
| Male | 2654 (50.26) | 796 (62.26) | 703 (51.53) | 637 (47.58) | 518 (37.62) | |
| Race, n (%) | 0.071 | |||||
| Non-Hispanic White | 2742 (74.17) | 675 (72.97) | 689 (75.17) | 653 (72.06) | 725 (76.55) | |
| Non-Hispanic Black | 969 (10.04) | 295 (11.63) | 241 (10.00) | 226 (10.16) | 207 (8.13) | |
| Mexican American | 1035 (7.35) | 213 (6.28) | 262 (7.28) | 303 (8.99) | 257 (7.03) | |
| Others | 338 (8.44) | 89 (9.12) | 81 (7.54) | 90 (8.79) | 78 (8.29) | |
| Education level, n (%) | < 0.001 | |||||
| Less than high school | 1402 (17.19) | 369 (20.54) | 366 (18.62) | 350 (14.88) | 317 (14.05) | |
| High school | 1251 (26.56) | 374 (32.54) | 327 (27.27) | 307 (26.22) | 243 (19.15) | |
| College or above | 2431 (56.25) | 529 (46.92) | 580 (54.11) | 615 (58.89) | 707 (66.80) | |
| Marital, n (%) | < 0.001 | |||||
| Married | 2860 (59.00) | 604 (51.55) | 711 (57.45) | 759 (61.29) | 786 (67.08) | |
| Separated | 1463 (25.48) | 410 (29.19) | 345 (25.28) | 344 (24.05) | 364 (22.82) | |
| Unmarried | 761 (15.52) | 258 (19.27) | 217 (17.27) | 169 (14.66) | 117 (10.10) | |
| Smoking status, n (%) | < 0.001 | |||||
| Never | 2493 (48.38) | 499 (38.37) | 584 (45.80) | 690 (54.38) | 720 (56.81) | |
| Former | 1426 (26.13) | 269 (19.62) | 358 (26.03) | 366 (26.83) | 433 (33.09) | |
| Now | 1165 (25.49) | 504 (42.01) | 331 (28.17) | 216 (18.79) | 114 (10.10) | |
| Alcohol user, n (%) | < 0.001 | |||||
| Never | 683 (11.53) | 115 (7.43) | 170 (11.85) | 179 (12.88) | 219 (14.57) | |
| Former | 1089 (17.45) | 244 (16.88) | 271 (17.76) | 296 (17.87) | 278 (17.35) | |
| Now | 3312 (71.02) | 913 (75.69) | 832 (70.40) | 797 (69.25) | 770 (68.08) | |
| Family of poverty ratio, n (%) | < 0.001 | |||||
| < 1.3 | 1286 (17.85) | 412 (23.55) | 331 (18.12) | 314 (16.55) | 229 (12.25) | |
| 1.3–3.5 | 2022 (37.34) | 509 (40.52) | 534 (40.16) | 488 (35.83) | 491 (32.02) | |
| >3.5 | 1776 (44.81) | 351 (35.93) | 408 (41.72) | 470 (47.62) | 547 (55.73) | |
| BMI (kg/m2) | 28.35 ± 0.12 | 30.09 ± 0.21 | 28.65 ± 0.24 | 28.07 ± 0.20 | 26.29 ± 0.18 | < 0.001 |
| Total cholesterol (mmol/L) | 5.16 ± 0.02 | 4.91 ± 0.03 | 5.09 ± 0.04 | 5.29 ± 0.04 | 5.39 ± 0.04 | < 0.001 |
| Leisure-time physical activity | < 0.001 | |||||
| Yes | 1356 (29.83) | 281 (22.79) | 336 (29.71) | 329 (29.84) | 410 (38.14) | |
| No | 3728 (70.17) | 991 (77.21) | 937 (70.29) | 943 (70.16) | 857 (61.86) | |
| CVD, n (%) | 0.460 | |||||
| Yes | 576 (8.31) | 132 (7.81) | 153 (9.20) | 131 (7.72) | 160 (8.49) | |
| No | 4508 (91.69) | 1140 (92.19) | 1120 (90.80) | 1141 (92.28) | 1107 (91.51) | |
| Hypertension, n (%) | 0.040 | |||||
| Yes | 2178 (36.59) | 560 (39.92) | 523 (36.35) | 542 (35.34) | 553 (34.24) | |
| No | 2906 (63.41) | 712 (60.08) | 750 (63.65) | 730 (64.66) | 714 (65.76) | |
| Diabetes, n (%) | 0.002 | |||||
| Yes | 650 (8.95) | 207 (11.89) | 159 (8.29) | 147 (7.70) | 137 (7.51) | |
| No | 4434 (91.05) | 1065 (88.11) | 1114 (91.71) | 1125 (92.30) | 1130 (92.49) | |
| α-carotene (ug/dL) | 4.24 ± 0.18 | 1.28 ± 0.04 | 2.48 ± 0.05 | 4.22 ± 0.13 | 9.66 ± 0.45 | < 0.001 |
| β-cryptoxanthin (ug/dL) | 8.93 ± 0.18 | 4.85 ± 0.10 | 7.22 ± 0.17 | 10.18 ± 0.24 | 14.33 ± 0.32 | < 0.001 |
| Lutein/zeaxanthin (ug/dL) | 15.58 ± 0.22 | 10.82 ± 0.17 | 13.84 ± 0.24 | 16.78 ± 0.25 | 21.82 ± 0.42 | < 0.001 |
| Trans-lycopene (ug/dL) | 23.05 ± 0.26 | 19.10 ± 0.34 | 23.43 ± 0.40 | 24.52 ± 0.41 | 25.74 ± 0.42 | < 0.001 |
All values are presented as number and proportion (%), or mean and SE.
Compared with the quartile 1 group, participants with the highest serum β-carotene concentration were patients who were older, female, better educated, married, never smokers, inclined to participate in leisure-time physical activity, had lower BMI, higher family income–poverty ratio level, and less likely to be diagnosed with diabetes and hypertension.
Association between serum carotenoid concentration and VAI and LAP
Three multiple regression models were conducted to determine the correlation of various carotenoids in the serum with VAI. In the crude model, the highest quartiles of five carotenoids were significantly associated with VAI compared with their respective lowest quartiles. after adjusting all covariates, the inverse association was robust between α-carotene (− 0.98 [95% CI, − 1.34 to − 0.62]), β-carotene (− 1.39, [95% CI, − 1.77 to − 1.00]), β-cryptoxanthin (− 0.79, [95% CI, − 1.18 to − 0.41]), lutein/zeaxanthin (− 0.68 (95% CI, − 0.96 to − 0.39]), trans-lycopene (− 0.88 [95% CI, − 1.50 to − 0.27]) with VAI (Table 2).
Table 2.
The associations of the quartile of serum carotenoids, relative to Quartile 1 with VAI
| Categories | Range | Model1 | Model2 | Model3 |
|---|---|---|---|---|
| β (95%CI) | β (95%CI) | β (95%CI) | ||
| α-carotene (ug/dL) | ||||
| Continuous | −0.29 (− 0.36, − 0.21) | −0.31 (− 0.39, − 0.23) | −0.25 (− 0.33, − 0.16) | |
| Q1 | < 1.40 | ref | ref | ref |
| Q2 | 1.40–2.70 | −0.47 (− 0.82, − 0.12) | −0.52 (− 0.88, − 0.16) | −0.49 (− 0.83, − 0.14) |
| Q3 | 2.70–5.00 | −0.64 (− 0.95, − 0.33) | −0.73 (− 1.05, − 0.40) | −0.70 (− 1.04, − 0.36) |
| Q4 | ≥ 5.00 | −0.93 (− 1.24, − 0.63) | −1.05 (− 1.38, − 0.72) | −0.98 (− 1.34, − 0.62) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| β-carotene (ug/dL) | ||||
| Continuous | −0.35 (− 0.47, − 0.24) | −0.41 (− 0.54, − 0.27) | −0.32 (− 0.44, − 0.20) | |
| Q1 | < 7.50 | ref | ref | ref |
| Q2 | 7.50–12.89 | −0.59 (− 0.93, − 0.26) | −0.65 (− 0.99, − 0.30) | −0.62 (− 0.97, − 0.26) |
| Q3 | 12.89–23.30 | −0.73 (− 1.01, − 0.46) | −0.86 (− 1.15, − 0.57) | −0.85 (− 1.17, − 0.54) |
| Q4 | > 23.30 | −1.28 (− 1.60, − 0.96) | −1.52 (− 1.87, − 1.17) | −1.39 (− 1.77, − 1.00) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| β-cryptoxanthin (ug/dL) | ||||
| Continuous | −0.26 (− 0.38, − 0.14) | −0.27 (− 0.39, − 0.14) | −0.28 (− 0.42, − 0.14) | |
| Q1 | < 4.80 | ref | ref | ref |
| Q2 | 4.80–7.70 | −0.42 (− 0.77, − 0.08) | −0.41 (− 0.75, − 0.07) | −0.42 (− 0.76, − 0.09) |
| Q3 | 7.70–12.70 | −0.60 (− 0.89, − 0.32) | −0.60 (− 0.88, − 0.32) | −0.57 (− 0.90, − 0.24) |
| Q4 | > 12.70 | −0.76 (− 1.08, − 0.43) | −0.78 (− 1.10, − 0.45) | −0.79 (− 1.18, − 0.41) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| Lutein/zeaxanthin (ug/dL) | ||||
| Continuous | −0.18 (− 0.28, − 0.08) | −0.23 (− 0.32, − 0.13) | −0.28 (− 0.39, − 0.16) | |
| Q1 | < 10.46 | ref | ref | ref |
| Q2 | 10.46–14.50 | −0.09 (− 0.41, 0.22) | −0.12 (− 0.43, 0.19) | −0.19 (− 0.46, 0.09) |
| Q3 | 14.50–20.10 | −0.42 (− 0.62, − 0.21) | −0.47 (− 0.68, − 0.27) | −0.54 (− 0.79, − 0.29) |
| Q4 | ≥ 20.10 | −0.40 (− 0.64, − 0.16) | −0.51 (− 0.75, − 0.27) | −0.68 (− 0.96, − 0.39) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| Trans-lycopene (ug/dL) | ||||
| Continuous | −0.12 (− 0.24, 0.00) | −0.08 (− 0.21, 0.04) | −0.33 (− 0.53, − 0.12) | |
| Q1 | < 14.00 | ref | ref | ref |
| Q2 | 14.00–20.11 | −0.48 (− 0.85, − 0.09) | −0.39 (− 0.78, 0.00) | −0.38 (− 0.81, 0.04) |
| Q3 | 20.11–28.23 | −0.39 (− 0.79, 0.00) | −0.28 (− 0.70, 0.14) | −0.46 (− 0.96, 0.04) |
| Q4 | ≥ 28.23 | −0.48 (− 0.87, − 0.10) | −0.38 (− 0.78, 0.02) | −0.88 (− 1.50, − 0.27) |
| P for trend | 0.023 | 0.104 | 0.005 |
Model 1: no cofounder; Model 2: adjusted for age, sex; Model 3: further adjusted for race, education level, marital status, alcohol intake, smoking status, leisure-time physical activity, BMI, the family of poverty ratio, TC, hypertension, diabetes, and CVD.
Five carotenoids were negatively correlated with LAP in the crude model (Table 3). When serum carotenoids were calculated as continuous variables, multivariate regression analysis revealed an inverse correlation between β-carotene, α-carotene, β-cryptoxanthin, trans-lycopene, and LAP. When they were divided into quartiles, the β values and 95% CIs of participants in fourth quartiles were (− 19.40 [− 25.47, − 13.32]) for α-carotene, (− 29.21 [− 35.21, − 23.22]) for β-carotene, (− 13.82 [− 19.59, − 8.05]) for β-cryptoxanthin, (− 10.11 [− 15.73, − 4.50]) for lutein/zeaxanthin, (− 15.65 [− 24.09, − 7.21]) for trans-lycopene after complete adjustment compared with the lowest quartile (Table 3).
Table 3.
The associations of the quartile of serum carotenoids, relative to Quartile 1 with LAP
| Categories | Model1 | Model2 | Model3 | |
|---|---|---|---|---|
| β (95%CI) | β (95%CI) | β (95%CI) | ||
| α-carotene (ug/dL) | ||||
| Continuous | −8.52 (− 10.44, − 6.59) | −8.97 (− 11.13, − 6.81) | −4.47 (− 6.10, − 2.84) | |
| Q1 | < 1.40 | Ref | Ref | Ref |
| Q2 | 1.40–2.70 | −12.25 (− 19.59, − 4.90) | −13.67 (− 21.18, − 6.15) | −10.46 (− 16.56, − 4.35) |
| Q3 | 2.70–5.00 | −17.54 (− 24.88, − 10.19) | −20.11 (− 27.56, − 12.66) | −14.49 (− 21.13, − 7.85) |
| Q4 | ≥ 5.00 | −27.71 (− 34.36, − 21.06) | −30.63 (− 37.71, − 23.54) | −19.40 (− 25.47, − 13.32) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| β-carotene (ug/dL) | ||||
| Continuous | −10.46 (− 13.49, − 7.43) | −11.98 (− 15.57, − 8.39) | −6.18 (− 8.13, − 4.22) | |
| Q1 | < 7.50 | Ref | Ref | Ref |
| Q2 | 7.50–12.89 | −18.45 (− 25.51, − 11.38) | −19.52 (− 26.63, − 12.41) | −14.50 (− 21.00, − 7.99) |
| Q3 | 12.89–23.30 | −21.99 (− 28.51, − 15.46) | −25.67 (− 32.11, − 19.23) | −18.84 (− 24.33, − 13.35) |
| Q4 | > 23.30 | −37.83 (− 43.99, − 31.67) | −44.69 (− 51.25, − 38.13) | −29.21 (− 35.21, − 23.22) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| β-cryptoxanthin (ug/dL) | ||||
| Continuous | −8.56 (− 11.19, − 5.92) | −8.71 (− 11.42, − 5.99) | −4.87 (− 7.05, − 2.69) | |
| Q1 | < 4.80 | Ref | Ref | Ref |
| Q2 | 4.80–7.70 | −12.11 (− 20.06, − 4.17) | −11.32 (− 19.19, − 3.46) | −8.55 (− 14.71, − 2.40) |
| Q3 | 7.70–12.70 | −17.88 (− 24.71, − 11.04) | −17.58 (− 24.07, − 11.09) | −10.72 (− 16.28, − 5.15) |
| Q4 | > 12.70 | −24.4 (− 30.58, − 18.23) | −24.83 (− 30.91, − 18.75) | −13.82 (− 19.59, − 8.05) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| Lutein/zeaxanthin (ug/dL) | ||||
| Continuous | −4.94 (− 7.31, − 2.57) | −6.88 (− 9.26, − 4.51) | −4.29 (− 6.35, − 2.22) | |
| Q1 | < 10.46 | Ref | Ref | Ref |
| Q2 | 10.46–14.50 | −2.2 (− 9.00, 4.61) | −3.63 (− 10.25, 2.98) | −2.76 (− 7.82, 2.31) |
| Q3 | 14.50–20.10 | −10.17 (− 15.38, − 4.97) | −12.78 (− 17.71, − 7.85) | −9.00 (− 13.64, − 4.37) |
| Q4 | ≥ 20.10 | −10.39 (− 16.33, − 4.46) | −15.3 (− 21.00, − 9.60) | −10.11 (− 15.73, − 4.50) |
| P for trend | < 0.001 | < 0.001 | < 0.001 | |
| Trans-lycopene (ug/dL) | ||||
| Continuous | −1.55 (− 4.01, 0.91) | −0.16 (− 2.74, 2.42) | −5.88 (− 8.62, − 3.13) | |
| Q1 | < 14.00 | Ref | Ref | Ref |
| Q2 | 14.00–20.11 | −9.74 (− 16.13, − 3.35) | −5.51 (− 11.88, 0.85) | −5.84 (− 12.49, 0.81) |
| Q3 | 20.11–28.23 | −8.04 (− 15.57, − 0.50) | −2.49 (− 10.37, 5.38) | −6.87 (− 14.42, 0.67) |
| Q4 | ≥ 28.23 | −8.55 (− 15.67, − 1.43) | −3.79 (− 11.20, 3.63) | −15.65 (− 24.09, − 7.21) |
| P for trend | 0.051 | 0.534 | < 0.001 |
Model 1: no cofounder; Model 2: adjusted for age, sex; Model 3: further adjusted for race, education level, marital status, alcohol intake, smoking status, leisure-time physical activity, BMI, the family of poverty ratio, TC, hypertension, diabetes, and CVD.
Piece-wise linear regression models revealed non-linear relationships between βcarotene and trans-lycopene and VAI with an inflection point of 2.44 (log2-transformed, ug/dL) and 3.80 (log2-transformed, ug/dL), respectively. The results indicated that α-carotene, β-cryptoxanthin, and lutein/zeaxanthin were linearly related to VAI. (Table 4; Fig. 2A–E)
Table 4.
Threshold effect analysis of serum carotenoids on VAI using piece-wise linear regression
| VAI | Adjusted β (95% CI) P value | |
|---|---|---|
| α-carotene | ||
| One line slop | −0.26 (− 0.31, − 0.20) < 0.0001 | |
| Log likelihood ratio test | 0.071 | |
| β-carotene | ||
| Inflection point (K) | 2.44 | |
| <K slope | −0.63 (− 0.89, − 0.37) < 0.0001 | |
| >K slope | −0.33 (− 0.40, − 0.25) < 0.0001 | |
| Log likelihood ratio test | 0.038 | |
| β-cryptoxanthin | ||
| One line slop | −0.24 (− 0.32, − 0.17) < 0.0001 | |
| Log likelihood ratio test | 0.447 | |
| Lutein/zeaxanthin | ||
| One line slop | −0.26 (− 0.37, − 0.15) < 0.0001 | |
| Log likelihood ratio test | 0.354 | |
| Trans-lycopene | ||
| Inflection point (K) | 3.80 | |
| <K slope | −0.11 (− 0.27, 0.06) 0.1966 | |
| >K slope | −0.47 (− 0.62, − 0.33) < 0.0001 | |
| Log likelihood ratio test | 0.005 |
Adjusted for age, sex, race, education level, marital status, alcohol intake, smoking status, leisure-time physical activity, BMI, the family of poverty ratio, TC, hypertension, diabetes, and CVD.
Fig. 2.
Association of specific serum Carotenoids with visceral adiposity index (α-carotene (A), β-carotene (B), β-cryptoxanthin (C), Lutein/zeaxanthin (D), Trans-lycopene (E)). Adjusted for age, sex, race, education level, marital status, alcohol intake, smoking status, leisure-time physical activity, BMI, the family of poverty ratio, TC, hypertension, diabetes, and CVD
Similarly, Table 5 showed that β-cryptoxanthin and lutein/zeaxanthin were linearly related to LAP, whereas α-carotene, βcarotene and trans-lycopene were non-linearly related to LAP with an inflection point of − 0.51 (log2-transformed, ug/dL), 2.93 (log2-transformed, ug/dL), and 4.29 (log2-transformed, ug/dL), respectively (Table 5; Fig. 3A–E).
Table 5.
Threshold effect analysis of serum carotenoids on LAP using piece-wise linear regression
| LAP | Adjusted β (95% CI) P value | |
|---|---|---|
| α-carotene | ||
| Inflection point (K) | −0.51 | |
| <K slope | −15.17 (− 24.33, − 6.02) 0.0012 | |
| >K slope | −4.94 (− 6.30, − 3.58) < 0.0001 | |
| Log likelihood ratio test | 0.038 | |
| β-carotene | ||
| Inflection point (K) | 2.93 | |
| <K slope | −13.56 (− 17.46, − 9.67) < 0.0001 | |
| >K slope | −6.52 (− 8.31, − 4.74) < 0.0001 | |
| Log likelihood ratio test | 0.004 | |
| β-cryptoxanthin | ||
| One line slop | −4.95 (− 6.57, − 3.34) < 0.0001 | |
| Log likelihood ratio test | 0.253 | |
| Lutein/zeaxanthin | ||
| One line slop | −4.03 (− 6.38, − 1.69) 0.0008 | |
| Log likelihood ratio test | 0.367 | |
| Trans-lycopene | ||
| Inflection point (K) | 4.29 | |
| <K slope | −2.66 (− 5.45, 0.13) 0.0613 | |
| >K slope | −12.00 (− 16.38, − 7.63) < 0.0001 | |
| Log likelihood ratio test | 0.002 |
Adjusted for age, sex, race, education level, marital status, alcohol intake, smoking status, leisure-time physical activity, BMI, the family of poverty ratio, TC, hypertension, diabetes, and CVD.
Fig. 3.
Association of specific serum Carotenoids with lipid accumulation product (α-carotene (A), β-carotene (B), β-cryptoxanthin (C), Lutein/zeaxanthin (D), Trans-lycopene (E)). Adjusted for age, sex, race, education level, marital status, alcohol intake, smoking status, leisure-time physical activity, BMI, the family of poverty ratio, TC, hypertension, diabetes, and CVD
Sensitivity analyses
Stratified analyses were performed to investigate the relation of specific serum carotenoids (per SD increment) with VAI or LAP. No significant interaction was found when data were stratified by sex, race, BMI, alcohol intake, smoking status, hypertension, and CVD (Supplementary Tables 1–5). Consistent outcomes were obtained when current smokers were excluded (Supplemental Table 6).
Discussion
This population-based study revealed that higher levels of serum carotenoids, including α-carotene, β-carotene, β-cryptoxanthin, lutein/zeaxanthin, and trans-lycopene, are correlated with lower VAI or LAP. Non-linear relationships were found among certain serum carotenoids and VAI or LAP. No significant interactions were found in subgroup analyses.
The dysregulation of lipid homeostasis is considered a common characteristic in several diseases, particularly metabolic disorders. Changes in lipid profiles often occur before the onset of diseases [28, 29]. Obesity-related physiological abnormalities are predominantly affected by the distribution of body fat, rather than solely attributed to the presence of overweight or obesity [30–32]. Notably, previous studies have reported a strong association between visceral fat, rather than subcutaneous fat, and metabolic risk factors [31].
In the sensitive detection of visceral fat, techniques such as computed tomography and magnetic resonance imaging are widely used. However, these methods have limitations such as high costs, time-consuming procedures, and potential radiation hazards. As a result, these techniques are not feasible for large-scale population screenings. Traditional indicators, including BMI and WC, can reflect the degree of overweight but they are limited in the capacity to assess fat distribution. Conversely, VAI and LAP have been recognized as novel markers for evaluating visceral fat in a simple and noninvasive manner. Unlike traditional lipid profiles, VAI and LAP can assess many metabolic disorder syndromes and provide a comprehensive assessment of the metabolic health of individuals [33–36].
The inverse correlation between serum carotenoids and VAI or LAP could be due to the antioxidant properties of carotenoids [37]. Oxidative stress increases the accumulation of white adipose tissue (WAT), stimulation of preadipocyte proliferation and differentiation, and enlargement of mature adipocytes [38]. Carotenoids play an important role in oxidative metabolism by inhibiting lipid peroxidation and participating in cell interactions involved in apoptosis [17, 18, 37]. Further, carotenoids are recognized as precursors to retinoids, which are considered to block the formation of adipocytes and decrease fat accumulation [39]. Retinoids inhibit the activation of peroxisome proliferator-activated receptor γ, a critical transcription factor required for fat accumulation in adipocytes [40]. Additionally, retinoic acid stimulates the upregulation of uncoupling protein-1 gene expression, which is crucial for facilitating the uncoupling of mitochondrial respiration [41, 42]. This plays an important role in decreasing fat accumulation within WAT [43]. Carotenoids can regulate insulin resistance and promote insulin secretion to decrease abdominal fat accumulation through the regulation of hormone-sensitive lipase [22, 44]. In this study, the adverse connection between five serum carotenoids and metabolic indicators, such as VAI and LAP, may be due to the aforementioned underlying mechanism. To conclude, carotenoids play a vital role in various stages of the lipid metabolic process.
Previous study has showed the correlation between carotenoids and obesity, obesity indices, and obesity-related diseases, across different epidemiological methodologies and target populations. Several epidemiological and observational studies have reported that both young and old people with obesity have lower plasma carotenoid concentrations [45–47]. Furthermore, levels of adipose carotenoids obtained from the buttock, abdomen, and inner thigh showed an inverse correlation with body fat mass [48]. β-carotene content in adipocytes collected from obese individuals was approximately half of that collected from individuals with normal weight [49]. In the Coronary Artery Risk Development in Young Adults study over seven years, the connection between the change in serum carotenoids (excluding lycopene) and the change in BMI was inversely related among non-smokers; however, this correlation was not observed among smokers [50]. A previous study conducted in the U.S. females also revealed a negative association between dietary lutein/zeaxanthin intake and metabolic syndrome, which is strongly associated with obesity and dyslipidemia [51]. Another intervention pilot study performed in obese middle-aged Japanese men with a BMI of ≥ 25 kg/m2 indicated that short-term consumption of lycopene and lutein decreased the intra-abdominal visceral fat, which is consistent with the adverse association between serum carotenoids and visceral fat indicators of this research [52]. However, the small sample size and lack of survey of other dietary intake restricted their outcomes.
In some interventional trials, the results showed carotenoids had no effect [20–22]. In healthy Japanese males, limited associations were found between obesity indicators, such as WC and waist-to-hip ratio and serum concentration of carotenoids including αcarotene and βcarotene [20]. This can be because approximately 70% of male participants in the study were heavy smokers, consuming over 20 cigarettes per day. The absence of a statistically significant correlation between the variables was most likely caused by the considerable effect of smoking on the blood concentration of carotenoids and obesity indices. Consistent with the the aforementioned studies, this study showed an inverse correlation between specific serum concentrations of carotenoids and VAI and LAP in a large-scale and normal U.S. population based on another metabolic trait and obesity phenotype different from unconventional indices.
Strengths and limitations
The present study has multiple strengths. The results were derived from a substantial, nationally representative sample, allowing for the weighted outcomes that reflect the U.S. population at the national level. Furthermore, a broad range of potential confounding factors were considered in this study and subgroup analyses were conducted to ensure consistent results. This study has limitations that should be addressed. We were incapable of establishing a causal relationship based on a cross-sectional study design, not longitudinal. Additionally, although several covariates were considered, there may still be residual confounders affecting the outcomes. More investigations are required to highlight the effect of smoking status on the concentration of serum carotenoids. Moreover, the relationship between total serum carotenoids and obesity indicators could not be established due to the incomplete total lycopene. Lastly, considering the complex metabolism of serum carotenoids in vivo, additional research should be taken into consideration.
Conclusion
To summarize, this study conducted was on the sample obtained from the nationally representative U.S. population. An inverse relationship was found between VAI or LAP and the serum concentrations of carotenoids after complete adjustments. The findings have potential public health implications and support the metabolic benefits of serum carotenoids on obesity and lipid metabolism in adults. However, to validate the causal relationship and elucidate the underlying mechanism, further investigations are required.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Acknowledgements
We thank the National Health and Nutrition Examination Surveys for providing the data.
Abbreviations
- VAI
Visceral adiposity index
- LAP
Lipid accumulation product
- NHANES
National Health and Nutrition Examination Survey
- WC
Waist circumference
- BMI
Body mass index
- CVD
Cardiovascular diseases
- NCHS
National Center for Health Statistics
- HPLC
High-performance liquid chromatography
- TG
Triglycerides
- HDL
High-density lipoprotein
- TC
Total cholesterol
- WAT
White adipose tissue
Authors’ contributions
Shaohua Yan: conceptualization, formal analysis, software, and writing-original draft. Siyu Chen: conceptualization and software. Yumiao Liu: formal analysis and writing-original draft. Hongbin Liang: investigation and writing-review draft. Xinlu Zhang: formal analysis and project administration. Qiuxia Zhang: conceptualization writing-review draft, and project administration. Jiancheng Xiu: validation and supervision.All authors have read and agreed to the published version of the manuscript.
Funding
The study was supported by the National Key R&D Program of China (2018YFC1312803), Guangzhou Key Research and Development Program (202206080014), and National Natural Science Foundation of China (81974266).
Data Availability
The survey data are publicly available on the internet for data users and researchers throughout the world (www.cdc.gov/nchs/nhanes/).
Declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
The studies involving human participants were reviewed and approved by NCHS Ethics Review Board. The participants provided their written informed consent to participate in this study.
Consent for publication
Not applicable.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Qiuxia Zhang, Email: qiuxia_lmh@126.com.
Jiancheng Xiu, Email: xiujch@163.com.
References
- 1.Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231–40. doi: 10.1016/S2213-8587(19)30026-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Haslam DW, James WP. Obes Lancet. 2005;366(9492):1197–209. doi: 10.1016/S0140-6736(05)67483-1. [DOI] [PubMed] [Google Scholar]
- 3.Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–2. doi: 10.2337/dc09-1825. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Kouli GM, Panagiotakos DB, Kyrou I, Georgousopoulou EN, Chrysohoou C, Tsigos C, et al. Visceral adiposity index and 10-year Cardiovascular Disease incidence: the ATTICA study. Nutr Metab Cardiovasc Dis. 2017;27(10):881–9. doi: 10.1016/j.numecd.2017.06.015. [DOI] [PubMed] [Google Scholar]
- 5.Zhang Z, Shi D, Zhang Q, Wang S, Liu K, Meng Q, et al. Visceral adiposity index (VAI), a powerful predictor of incident Hypertension in prehypertensives. Intern Emerg Med. 2018;13(4):509–16. doi: 10.1007/s11739-018-1836-8. [DOI] [PubMed] [Google Scholar]
- 6.Martyniak K, Masternak MM. Changes in adipose tissue cellular composition during obesity and aging as a cause of metabolic dysregulation. Exp Gerontol. 2017;94:59–63. doi: 10.1016/j.exger.2016.12.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY, Wu KD. Metabolic syndrome and insulin resistance as risk factors for development of chronic Kidney Disease and rapid decline in renal function in elderly. J Clin Endocrinol Metab. 2012;97(4):1268–76. doi: 10.1210/jc.2011-2658. [DOI] [PubMed] [Google Scholar]
- 8.Oh JY, Sung YA, Lee HJ. The lipid accumulation product as a useful index for identifying abnormal glucose regulation in young Korean women. Diabet Med. 2013;30(4):436–42. doi: 10.1111/dme.12052. [DOI] [PubMed] [Google Scholar]
- 9.Chen J, Sun H, Qiu S, Tao H, Yu J, Sun Z. Lipid Accumulation Product Combined with urine glucose excretion improves the efficiency of Diabetes screening in Chinese adults. Front Endocrinol (Lausanne) 2021;12:691849. doi: 10.3389/fendo.2021.691849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Yan P, Xu Y, Miao Y, Tang Q, Wu Y, Bai X, et al. Association of lipid accumulation product with chronic Kidney Disease in Chinese community adults: a report from the REACTION study. Lipids Health Dis. 2021;20(1):131. doi: 10.1186/s12944-021-01569-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obes (Silver Spring) 2010;18(9):1836–44. doi: 10.1038/oby.2009.453. [DOI] [PubMed] [Google Scholar]
- 12.Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011;364(25):2392–404. doi: 10.1056/NEJMoa1014296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing Progressive Disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–23. doi: 10.1111/obr.12551. [DOI] [PubMed] [Google Scholar]
- 14.Khachik F, Spangler CJ, Smith JC, Jr, Canfield LM, Steck A, Pfander H. Identification, quantification, and relative concentrations of carotenoids and their metabolites in human milk and serum. Anal Chem. 1997;69(10):1873–81. doi: 10.1021/ac961085i. [DOI] [PubMed] [Google Scholar]
- 15.Mueller L, Boehm V. Antioxidant activity of β-carotene compounds in different in vitro assays. Molecules. 2011;16(2):1055–69. doi: 10.3390/molecules16021055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and Disease. Mol Aspects Med. 2005;26(6):459–516. doi: 10.1016/j.mam.2005.10.001. [DOI] [PubMed] [Google Scholar]
- 17.Ribeiro D, Freitas M, Silva AMS, Carvalho F, Fernandes E. Antioxidant and pro-oxidant activities of carotenoids and their oxidation products. Food Chem Toxicol. 2018;120:681–99. doi: 10.1016/j.fct.2018.07.060. [DOI] [PubMed] [Google Scholar]
- 18.do Nascimento TC, Cazarin CBB, Maróstica MR, Jr, Mercadante AZ, Jacob-Lopes E, Zepka LQ. Microalgae carotenoids intake: influence on cholesterol levels, lipid peroxidation and antioxidant enzymes. Food Res Int. 2020;128:108770. doi: 10.1016/j.foodres.2019.108770. [DOI] [PubMed] [Google Scholar]
- 19.Kakutani R, Hokari S, Nishino A, Ichihara T, Sugimoto K, Takaha T, et al. Effect of oral paprika Xanthophyll Intake on Abdominal Fat in healthy overweight humans: a Randomized, Double-blind, placebo-controlled study. J Oleo Sci. 2018;67(9):1149–62. doi: 10.5650/jos.ess18076. [DOI] [PubMed] [Google Scholar]
- 20.Suzuki K, Inoue T, Hioki R, Ochiai J, Kusuhara Y, Ichino N, et al. Association of abdominal obesity with decreased serum levels of carotenoids in a healthy Japanese population. Clin Nutr. 2006;25(5):780–9. doi: 10.1016/j.clnu.2006.01.025. [DOI] [PubMed] [Google Scholar]
- 21.Pourahmadi Z, Mahboob S, Saedisomeolia A, Reykandeh MT. The Effect of Tomato Juice Consumption on antioxidant status in overweight and obese females. Women Health. 2015;55(7):795–804. doi: 10.1080/03630242.2015.1050546. [DOI] [PubMed] [Google Scholar]
- 22.Yao N, Yan S, Guo Y, Wang H, Li X, Wang L, et al. The association between carotenoids and subjects with overweight or obesity: a systematic review and meta-analysis. Food Funct. 2021;12(11):4768–82. doi: 10.1039/D1FO00004G. [DOI] [PubMed] [Google Scholar]
- 23.Laboratory Procedure Manual: Fat Soluble Micronutrients. (2008). National Health and Nutrition Examination Survey, 1–45. [https://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l45vit_c_met_vitae_carotenoids.pdf].
- 24.Kahn HS. The lipid accumulation product performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26. doi: 10.1186/1471-2261-5-26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Centers for Disease Control and Prevention. About the national health and nutrition examination survey. [https://www.cdc.gov/nchs/nhanes/about_nhanes.htm].
- 26.Maiani G, Castón MJ, Catasta G, Toti E, Cambrodón IG, Bysted A, et al. Carotenoids: actual knowledge on food sources, intakes, stability and bioavailability and their protective role in humans. Mol Nutr Food Res. 2009;53(Suppl 2):194–218. doi: 10.1002/mnfr.200800053. [DOI] [PubMed] [Google Scholar]
- 27.Weber D, Grune T. The contribution of β-carotene to vitamin A supply of humans. Mol Nutr Food Res. 2012;56(2):251–8. doi: 10.1002/mnfr.201100230. [DOI] [PubMed] [Google Scholar]
- 28.Markgraf DF, Al-Hasani H, Lehr S. Lipidomics-reshaping the analysis and perception of type 2 Diabetes. Int J Mol Sci. 2016;17(11). [DOI] [PMC free article] [PubMed]
- 29.Knebel B, Strassburger K, Szendroedi J, Kotzka J, Scheer M, Nowotny B, et al. Specific metabolic profiles and their relationship to Insulin Resistance in recent-onset type 1 and type 2 Diabetes. J Clin Endocrinol Metab. 2016;101(5):2130–40. doi: 10.1210/jc.2015-4133. [DOI] [PubMed] [Google Scholar]
- 30.Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, et al. Body fat distribution and risk of coronary Heart Disease in men and women in the European prospective investigation into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation. 2007;116(25):2933–43. doi: 10.1161/CIRCULATIONAHA.106.673756. [DOI] [PubMed] [Google Scholar]
- 31.Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8. doi: 10.1111/j.1467-789X.2009.00623.x. [DOI] [PubMed] [Google Scholar]
- 32.Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–7. doi: 10.1038/nature05488. [DOI] [PubMed] [Google Scholar]
- 33.Wang J, Jin X, Chen K, Yan W, Wang A, Zhu B, et al. Visceral adiposity index is closely associated with urinary albumin-creatinine ratio in the Chinese population with prediabetes. Diabetes Metab Res Rev. 2021;37(7):e3424. doi: 10.1002/dmrr.3424. [DOI] [PubMed] [Google Scholar]
- 34.Murai J, Nishizawa H, Otsuka A, Fukuda S, Tanaka Y, Nagao H, et al. Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation. Cardiovasc Diabetol. 2018;17(1):112. doi: 10.1186/s12933-018-0755-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Chen ZY, Liu L, Zhuang XX, Zhang YC, Ma YN, Liu Y, et al. Lipid accumulation product is a better predictor of metabolic syndrome in Chinese adolescents: a cross-sectional study. Front Endocrinol (Lausanne) 2023;14:1179990. doi: 10.3389/fendo.2023.1179990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Choi MH, Choi JI, Park MY, Rha SE, Oh SN, Jung SE, et al. Validation of intimate correlation between visceral fat and hepatic steatosis: quantitative measurement techniques using CT for area of fat and MR for hepatic steatosis. Clin Nutr. 2018;37(1):214–22. doi: 10.1016/j.clnu.2016.12.006. [DOI] [PubMed] [Google Scholar]
- 37.Xavier AA, Pérez-Gálvez A. Carotenoids as a source of antioxidants in the Diet. Subcell Biochem. 2016;79:359–75. doi: 10.1007/978-3-319-39126-7_14. [DOI] [PubMed] [Google Scholar]
- 38.Thomas-Valdés S, Tostes M, Anunciação PC, da Silva BP, Sant’Ana HMP. Association between vitamin deficiency and metabolic disorders related to obesity. Crit Rev Food Sci Nutr. 2017;57(15):3332–43. doi: 10.1080/10408398.2015.1117413. [DOI] [PubMed] [Google Scholar]
- 39.Lobo GP, Amengual J, Li HN, Golczak M, Bonet ML, Palczewski K, et al. Beta,beta-carotene decreases peroxisome proliferator receptor gamma activity and reduces lipid storage capacity of adipocytes in a beta,beta-carotene oxygenase 1-dependent manner. J Biol Chem. 2010;285(36):27891–9. doi: 10.1074/jbc.M110.132571. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Kamei Y, Kawada T, Mizukami J, Sugimoto E. The prevention of adipose differentiation of 3T3-L1 cells caused by retinoic acid is elicited through retinoic acid receptor alpha. Life Sci. 1994;55(16):Pl307–312. doi: 10.1016/0024-3205(94)90073-6. [DOI] [PubMed] [Google Scholar]
- 41.Blaner WS. Vitamin A signaling and homeostasis in obesity, Diabetes, and metabolic disorders. Pharmacol Ther. 2019;197:153–78. doi: 10.1016/j.pharmthera.2019.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Murholm M, Isidor MS, Basse AL, Winther S, Sørensen C, Skovgaard-Petersen J, et al. Retinoic acid has different effects on UCP1 expression in mouse and human adipocytes. BMC Cell Biol. 2013;14:41. doi: 10.1186/1471-2121-14-41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Palou A, Picó C, Bonet ML. Nutritional potential of metabolic remodelling of white adipose tissue. Curr Opin Clin Nutr Metab Care. 2013;16(6):650–6. doi: 10.1097/MCO.0b013e328365980f. [DOI] [PubMed] [Google Scholar]
- 44.Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218–40. doi: 10.3390/nu5041218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.García OP, Long KZ, Rosado JL. Impact of micronutrient deficiencies on obesity. Nutr Rev. 2009;67(10):559–72. doi: 10.1111/j.1753-4887.2009.00228.x. [DOI] [PubMed] [Google Scholar]
- 46.Yeum KJ, Booth SL, Roubenoff R, Russell RM. Plasma carotenoid concentrations are inversely correlated with fat mass in older women. J Nutr Health Aging. 1998;2(2):79–83. [PubMed] [Google Scholar]
- 47.Sarni RO, Suano de Souza FI, Ramalho RA, Schoeps Dde O, Kochi C, Catherino P, et al. Serum retinol and total carotene concentrations in obese pre-school children. Med Sci Monit. 2005;11(11):Cr510–514. [PubMed] [Google Scholar]
- 48.Chung HY, Ferreira AL, Epstein S, Paiva SA, Castaneda-Sceppa C, Johnson EJ. Site-specific concentrations of carotenoids in adipose tissue: relations with dietary and serum carotenoid concentrations in healthy adults. Am J Clin Nutr. 2009;90(3):533–9. doi: 10.3945/ajcn.2009.27712. [DOI] [PubMed] [Google Scholar]
- 49.Östh M, Öst A, Kjolhede P, Strålfors P. The concentration of β-carotene in human adipocytes, but not the whole-body adipocyte stores, is reduced in obesity. PLoS ONE. 2014;9(1):e85610. doi: 10.1371/journal.pone.0085610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Andersen LF, Jacobs DR, Jr, Gross MD, Schreiner PJ, Dale Williams O, Lee DH. Longitudinal associations between body mass index and serum carotenoids: the CARDIA study. Br J Nutr. 2006;95(2):358–65. doi: 10.1079/BJN20051638. [DOI] [PubMed] [Google Scholar]
- 51.Zhang Y, Knol LL, Tan L. Association between Dietary Lutein/Zeaxanthin Intake and metabolic syndrome among US females: An Analysis of National Health and examination surveys 2015–2018. Curr Dev Nutr. 2021;5(10):nzab123. doi: 10.1093/cdn/nzab123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Takagi T, Hayashi R, Nakai Y, Okada S, Miyashita R, Yamada M et al. Dietary intake of Carotenoid-Rich vegetables reduces visceral adiposity in obese Japanese men-A Randomized, Double-Blind Trial. Nutrients. 2020;12(8). [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The survey data are publicly available on the internet for data users and researchers throughout the world (www.cdc.gov/nchs/nhanes/).